Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, December 22 '24)

Image
By G.M.

 


    Antiviral Res

  1. WELCH SR, Bilello JP, Carter K, Delang L, et al
    Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research.
    Antiviral Res. 2024;232:106037.
    PubMed         Abstract available

  2. WANG B, Xia H, Peng BH, Choi EJ, et al
    Pellino-1, a therapeutic target for control of SARS-CoV-2 infection and disease severity.
    Antiviral Res. 2024;233:106059.
    PubMed         Abstract available

  3. SHANNON A, Canard B
    Nucleotide analogues and mpox: Repurposing the repurposable.
    Antiviral Res. 2024;234:106057.
    PubMed         Abstract available


    BMJ

  4. FLYNN SG, Park RS, Jena AB, Staffa SJ, et al
    Coaching inexperienced clinicians before a high stakes medical procedure: randomized clinical trial.
    BMJ. 2024;387:e080924.
    PubMed         Abstract available

  5. PATERLINI M
    Italy abolishes fines for refusing covid-19 vaccination.
    BMJ. 2024;387:q2833.
    PubMed        

  6. BONCYK C, Rolfsen ML, Richards D, Stollings JL, et al
    Management of pain and sedation in the intensive care unit.
    BMJ. 2024;387:e079789.
    PubMed         Abstract available

  7. DYER O
    Covid-19 originated in Wuhan lab, alleges Republican congressional report.
    BMJ. 2024;387:q2765.
    PubMed        


    Br J Anaesth

  8. GLASBEY J, Webb SA, Peel T, Pinkney TD, et al
    Global collaboration between platform trials in surgery and anaesthesia.
    Br J Anaesth. 2024 Dec 18:S0007-0912(24)00576-2. doi: 10.1016/j.bja.2024.
    PubMed         Abstract available

  9. YAN F, Yang M
    Tracheostomy outcomes in critically ill patients with COVID-19: a systematic review, meta-analysis, and meta-regression. Comment on Br J Anaesth 2022; 129: 679-92.
    Br J Anaesth. 2024 Dec 12:S0007-0912(24)00680-9. doi: 10.1016/j.bja.2024.
    PubMed        


    Clin Infect Dis

  10. KONKLE SL, Magleby R, Bonacci RA, Segaloff HE, et al
    Post-COVID Condition Risk Factors and Symptom Clusters and Associations with Return to Pre-COVID Health-Results from a 2021 Multi-State Survey.
    Clin Infect Dis. 2024 Dec 20:ciae632. doi: 10.1093.
    PubMed         Abstract available

  11. HERBERT C, Antar AAR, Broach J, Wright C, et al
    Relationship Between Acute Severe Acute Respiratory Syndrome Coronavirus 2 Viral Clearance and Long Coronavirus 2019 (Long COVID) Symptoms: A Cohort Study.
    Clin Infect Dis. 2024 Dec 18:ciae539. doi: 10.1093.
    PubMed         Abstract available

  12. ANTOON JW, Amarin JZ, Hamdan O, Stopczynski T, et al
    Antiviral Use Among Children Hospitalized With Laboratory-Confirmed Influenza Illness: A Prospective, Multicenter Surveillance Study.
    Clin Infect Dis. 2024 Dec 17:ciae573. doi: 10.1093.
    PubMed         Abstract available

  13. RAWSON JMO, Donaldson EF, O'Rear JJ, Harrington PR, et al
    Independent FDA Analyses of Nirmatrelvir/Ritonavir Resistance in the Phase 2/3 Trials EPIC-HR and EPIC-SR.
    Clin Infect Dis. 2024 Dec 17:ciae615. doi: 10.1093.
    PubMed         Abstract available

  14. WEE LE, Lim JT, Goel M, Malek MIA, et al
    Bivalent boosters and risk of post-acute sequelae following vaccine-breakthrough SARS-CoV-2 Omicron infection: a cohort study.
    Clin Infect Dis. 2024 Dec 5:ciae598. doi: 10.1093.
    PubMed         Abstract available

  15. PINANA JL, Carbonell-Asins JA, Gomez D, Montoro J, et al
    Community-Acquired Respiratory Virus Infections: A Threat to Long-Term survivors after Allogeneic Stem Cell Transplant?
    Clin Infect Dis. 2024 Dec 5:ciae602. doi: 10.1093.
    PubMed         Abstract available

  16. SHITTU I, Silva D, Oguzie JU, Marushchak LV, et al
    A One Health Investigation into H5N1 Avian Influenza Virus Epizootics on Two Dairy Farms.
    Clin Infect Dis. 2024 Dec 10:ciae576. doi: 10.1093.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  17. LINKENHELD A, Williams VR, Chan K, Carating H, et al
    Impact of daily prompt to vaccinate inpatients awaiting rehabilitation against SARS-CoV-2 and influenza.
    Infect Control Hosp Epidemiol. 2024 Dec 19:1-3. doi: 10.1017/ice.2024.
    PubMed         Abstract available


    Int J Infect Dis

  18. SIBOMANA O, Hakayuwa CM, Munyantore J
    Marburg Virus Reaches Rwanda: How Close Are We to a Vaccine Solution?
    Int J Infect Dis. 2024 Dec 19:107371. doi: 10.1016/j.ijid.2024.107371.
    PubMed         Abstract available

  19. ANDEWEG SP, de Kassteele JV, Wang X, van Maarseveen N, et al
    Estimating the effect of COVID-19 vaccination and prior infection on Ct values as a proxy of SARS-CoV-2 viral load.
    Int J Infect Dis. 2024 Dec 9:107362. doi: 10.1016/j.ijid.2024.107362.
    PubMed         Abstract available

  20. WATASE M, Masaki K, Chubachi S, Namkoong H, et al
    Corrigendum to 'Impact of accumulative smoking exposure and chronic obstructive pulmonary disease on COVID-19 outcomes: report based on findings from the Japan COVID-19 task force' [IJID 128 (2023) 121-127].
    Int J Infect Dis. 2024;151:107322.
    PubMed        

  21. DEQUIDT T, Richier Q, Louapre C, Ader F, et al
    Convalescent plasma in patients receiving Rituximab or Ocrelizumab for Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder with COVID-19: A Multicenter Retrospective Study.
    Int J Infect Dis. 2024 Dec 4:107323. doi: 10.1016/j.ijid.2024.107323.
    PubMed         Abstract available


    J Infect

  22. CHOW KN, Tsang YW, Chan YH, Telaga SA, et al
    The effect of pre-COVID and post-COVID vaccination on long COVID: a systematic review and meta-analysis.
    J Infect. 2024 Nov 21:106358. doi: 10.1016/j.jinf.2024.106358.
    PubMed         Abstract available

  23. MOK CKP, Tang YS, Tan CW, Chong KC, et al
    Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine.
    J Infect. 2024;90:106374.
    PubMed         Abstract available


    J Med Virol

  24. HUANG J, Li Y, Chen H, Liu H, et al
    Epidemiological, Clinical, and Genomic Traits of PIV in Hospitalized Children After the COVID-19 Pandemic in Wuhan, China.
    J Med Virol. 2024;96:e70117.
    PubMed         Abstract available

  25. CHAN YJ, Chen CC, Tu YK, Hsu WH, et al
    The Effectiveness of COVID-19 Vaccination on Post-Acute Sequelae of SARS-CoV-2 Infection Among Geriatric Patients.
    J Med Virol. 2024;96:e70119.
    PubMed         Abstract available

  26. VLAMING-VAN EIJK LE, Ertugrul IA, Upasani V, Wold KI, et al
    Temporal Dynamics and (Para)Clinical Factors Associated With (Long) Viral RNA Shedding in COVID-19 Nonhospitalized Individuals - The COVID-HOME Study.
    J Med Virol. 2024;96:e70125.
    PubMed         Abstract available

  27. DALEXIS RD, Moshirian Farahi SMM, Dort J, Beogo I, et al
    Rates and Factors Related to COVID-19 Vaccine Uptake in Racialized and Indigenous Individuals in Canada: The Deleterious Effect of Experience of Racial Discrimination.
    J Med Virol. 2024;96:e70127.
    PubMed         Abstract available

  28. LAURE C, Hanae PR, Helene C, Melanie F, et al
    COVID-19 and Oncofertility: No SARS-CoV-2 in Semen but Inflammation Seems to Affect Sperm Parameters.
    J Med Virol. 2024;96:e70070.
    PubMed         Abstract available

  29. MANRIQUE JM, Maffia-Bizzozero S, Delpino MV, Quarleri J, et al
    Multi-Organ Spread and Intra-Host Diversity of SARS-CoV-2 Support Viral Persistence, Adaptation, and a Mechanism That Increases Evolvability.
    J Med Virol. 2024;96:e70107.
    PubMed         Abstract available


    J Virol

  30. BARBOSA BOMFIM CC, Genin H, Cottoignies-Callamarte A, Gallois-Montbrun S, et al
    Erratum for Barbosa Bomfim et al., "CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients".
    J Virol. 2024 Dec 10:e0200624. doi: 10.1128/jvi.02006.
    PubMed        

  31. CARDANI-BOULTON A, Lin F, Bergmann CC
    CD6 regulates CD4 T follicular helper cell differentiation and humoral immunity during murine coronavirus infection.
    J Virol. 2024 Dec 16:e0186424. doi: 10.1128/jvi.01864.
    PubMed         Abstract available

  32. CAI Z, Ni W, Li W, Wu Z, et al
    SARS-CoV-2 S protein disrupts the formation of ISGF3 complex through conserved S2 subunit to antagonize type I interferon response.
    J Virol. 2024 Dec 19:e0151624. doi: 10.1128/jvi.01516.
    PubMed         Abstract available


    JAMA

  33. MAIA IS, Kawano-Dourado L, Tramujas L, de Oliveira NE, et al
    High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial.
    JAMA. 2024 Dec 10. doi: 10.1001/jama.2024.26244.
    PubMed         Abstract available

  34. ANDERER S
    Trial Shows It's Safe to Get COVID-19, Flu Vaccines at the Same Time.
    JAMA. 2024 Dec 13. doi: 10.1001/jama.2024.24891.
    PubMed        

  35. ANDERER S
    New Research Suggests Increased Risk of Some Autoimmune Disorders After COVID-19.
    JAMA. 2024 Dec 13. doi: 10.1001/jama.2024.24894.
    PubMed        

  36. GENG LN, Erlandson KM, Hornig M, Letts R, et al
    2024 Update of the RECOVER-Adult Long COVID Research Index.
    JAMA. 2024 Dec 18. doi: 10.1001/jama.2024.24184.
    PubMed         Abstract available

  37. RUBIN R
    In Search of COVID-19 Vaccines That Elicit Mucosal Immunity and Stop Transmission.
    JAMA. 2024 Dec 20. doi: 10.1001/jama.2024.23627.
    PubMed        


    Lancet


  38. The burden of diseases, injuries, and risk factors by state in the USA, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024;404:2314-2340.
    PubMed         Abstract available

  39. DZAU VJ, Laitner MH, Shambaugh EL
    Strategic imperatives for health in the USA: a roadmap for the incoming presidential administration.
    Lancet. 2024;404:2371-2379.
    PubMed         Abstract available


  40. Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2025;404:2543-2583.
    PubMed         Abstract available

  41. RUBIN DT, Allegretti JR, Panes J, Shipitofsky N, et al
    Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
    Lancet. 2024 Dec 17:S0140-6736(24)01927-5. doi: 10.1016/S0140-6736(24)01927.
    PubMed         Abstract available


    Lancet Infect Dis

  42. ROJEK A, Fieggen J, Apiyo P, Caluwaerts S, et al
    Ebola disease: bridging scientific discoveries and clinical application.
    Lancet Infect Dis. 2024 Dec 12:S1473-3099(24)00673.
    PubMed         Abstract available

  43. URIU K, Kaku Y, Uwamino Y, Fujiwara H, et al
    Antiviral humoral immunity induced by JN.1 monovalent mRNA vaccines against SARS-CoV-2 omicron subvariants including JN.1, KP.3.1.1, and XEC.
    Lancet Infect Dis. 2024 Dec 10:S1473-3099(24)00810.
    PubMed        


    Life Sci

  44. OATIS D, Balta C, Herman H, Ciceu A, et al
    The interplay between lung galectins and pro-fibrotic markers in post-COVID-19 fibrogenesis: A pilot study.
    Life Sci. 2024 Dec 19:123326. doi: 10.1016/j.lfs.2024.123326.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  45. ABDIRIZAK F, Winn AK, Parikh R, Scobie HM, et al
    Surveillance of Human Adenovirus Types and the Impact of the COVID-19 Pandemic on Reporting - United States, 2017-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:1136-1141.
    PubMed         Abstract available


    Nature

  46. MEYER C, Garzia A, Miller MW, Huggins DJ, et al
    Small-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase.
    Nature. 2024 Dec 11. doi: 10.1038/s41586-024-08320.
    PubMed         Abstract available

  47. VAN NOORDEN R
    Controversial COVID study that promoted unproven treatment retracted after four-year saga.
    Nature. 2024 Dec 18. doi: 10.1038/d41586-024-04014.
    PubMed        

  48. GRAHAM F
    Daily briefing: Infamous 'hydroxychloroquine for COVID-19' paper has been retracted.
    Nature. 2024 Dec 18. doi: 10.1038/d41586-024-04236.
    PubMed        


    Radiology

  49. HENDRICK RE, Monticciolo DL
    Surveillance, Epidemiology, and End Results Data Show Increasing Rates of Distant-Stage Breast Cancer at Presentation in U.S. Women.
    Radiology. 2024;313:e241397.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »